These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24864619)

  • 41. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
    Bloomgarden ZT; Blonde L; Garber AJ; Wysham CH
    Endocr Pract; 2012; 18 Suppl 3():6-26; quiz 27-8. PubMed ID: 23315305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GLP-1 receptor agonists today.
    Marre M; Penfornis A
    Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evidence for achieving glycemic control with incretin mimetics.
    Drucker DJ
    Diabetes Educ; 2006; 32 Suppl 2():72S-81S. PubMed ID: 16554431
    [No Abstract]   [Full Text] [Related]  

  • 46. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
    Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print].
    Valencia WM; Florez HJ
    J Med Econ; 2015; 18(12):1029-31. PubMed ID: 26337323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
    Kannan S; Nasr C
    Cleve Clin J Med; 2015 Mar; 82(3):142-4. PubMed ID: 25932736
    [No Abstract]   [Full Text] [Related]  

  • 51. The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.
    Režić T; Blaslov K; Kruljac I; Rahelić D; Vrkljan M; Renar IP
    Med Hypotheses; 2019 Oct; 131():109308. PubMed ID: 31443779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies.
    Tanday N; Flatt PR; Irwin N
    Diabet Med; 2021 Dec; 38(12):e14699. PubMed ID: 34562330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.
    Frias PF; Frias JP
    Curr Diab Rep; 2017 Aug; 17(10):91. PubMed ID: 28822051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists.
    Sesti G
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S272-5. PubMed ID: 21525467
    [No Abstract]   [Full Text] [Related]  

  • 57. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.
    Issa CM; Azar ST
    Curr Diab Rep; 2012 Oct; 12(5):560-7. PubMed ID: 22767380
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.
    Yammine L; Kosten TR; Pimenova M; Schmitz JM
    Diabetes Res Clin Pract; 2019 Mar; 149():78-88. PubMed ID: 30735771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
    Artigas CF; Stokes V; Tan GD; Theodorakis MJ
    Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucagon-like peptide-1 receptor agonists for intensifying diabetes treatment.
    Bush MA
    J Fam Pract; 2011 Sep; 60(9 Suppl):S11-20. PubMed ID: 21912773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.